Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804583 · ClinicalTrials.gov registry record
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
A clinical trial of Cystic Fibrosis and Liver Disease, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- 154
- Enrollment target
- 1
- Study location
NCT00804583 is a study of Cystic Fibrosis and Liver Disease that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 154 participants, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00804583, a study of Cystic Fibrosis and Liver Disease, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- 154 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines "modifier genes" that may play a role in the development of CF liver disease. Modifier genes are genes, other than the CF gene (CFTR), which may directly or indirectly have an affect on how the body responds to the conditions that develop as the result of the defective CFTR gene. Scientists have wondered why some patients with CF develop CF liver disease and why some patients with CF do not. To better understand the problem, this study was designed to examine the genetic makeup of CF patients who are considered to have severe liver disease to see if they can identify any modifier genes. Researchers will study blood samples, pulmonary function tests, and other medical information in hopes that a connection can be made between genetic make-up and how severe the liver disease is. The identification of modifier genes that influence disease severity may ultimately lead to a better understanding of CF liver disease, and may be useful in the development of new treatments.
Conditions Studied
Study Locations (1)
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2004-03 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00804583
The ClinicalTrials.gov registry entry for NCT00804583 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (13% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT00804583 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00804583 about?
NCT00804583 is a clinical study titled "Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease". This study examines "modifier genes" that may play a role in the development of CF liver disease. Modifier genes are genes, other than the CF gene (CFTR), which may directly or indirectly have an affect on how the body responds to the conditions that develop as the result of the defective CFTR gene....
What is the current status of trial NCT00804583?
This trial is currently active not recruiting. The enrollment target is 154 participants. The study started on 2004-03. Estimated completion is 2027-07.
What conditions does trial NCT00804583 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Liver Disease.
Who is sponsoring clinical trial NCT00804583?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00804583 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.